• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

坦桑尼亚医护人员对冠状病毒的中和免疫。

Neutralizing immunity against coronaviruses in Tanzanian health care workers.

机构信息

Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.

Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.

出版信息

Sci Rep. 2024 Mar 6;14(1):5508. doi: 10.1038/s41598-024-55989-4.

DOI:10.1038/s41598-024-55989-4
PMID:38448564
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10917759/
Abstract

The ongoing vaccination efforts and exposure to endemic and emerging coronaviruses can shape the population's immunity against this group of viruses. In this study, we investigated neutralizing immunity against endemic and emerging coronaviruses in 200 Tanzanian frontline healthcare workers (HCWs). Despite low vaccination rates (19.5%), we found a high SARS-CoV-2 seroprevalence (94.0%), indicating high exposure in these HCWs. Next, we determined the neutralization capacity of antisera against human coronavirus NL63, and 229E, SARS-CoV-1, MERS-CoV and SARS-CoV-2 (including Omicron subvariants: BA.1, BQ.1.1 and XBB.1.5) using pseudovirus neutralization assay. We observed a broad range of neutralizing activity in HCWs, but no neutralization activity detected against MERS-CoV. We also observed a strong correlation between neutralizing antibody titers for SARS-CoV-2 and SARS-CoV-1, but not between other coronaviruses. Cross-neutralization titers against the newer Omicron subvariants, BQ.1.1 and XBB.1.5, was significantly reduced compared to BA.1 and BA.2 subvariants. On the other hand, the exposed vaccinated HCWs showed relatively higher median cross-neutralization titers against both the newer Omicron subvariants and SARS-CoV-1, but did not reach statistical significance. In summary, our findings suggest a broad range of neutralizing potency against coronaviruses in Tanzanian HCWs with detectable neutralizing immunity against SARS-CoV-1 resulting from SARS-CoV-2 exposure.

摘要

在坦桑尼亚,正在进行的疫苗接种工作以及对地方性和新兴冠状病毒的接触,可能会影响该人群对这组病毒的免疫力。在这项研究中,我们调查了 200 名坦桑尼亚一线医护人员(HCWs)对地方性和新兴冠状病毒的中和免疫情况。尽管疫苗接种率较低(19.5%),但我们发现 SARS-CoV-2 的血清阳性率很高(94.0%),表明这些 HCWs 中有很高的暴露率。接下来,我们使用假病毒中和试验测定了抗人冠状病毒 NL63 和 229E、SARS-CoV-1、MERS-CoV 和 SARS-CoV-2(包括奥密克戎亚变种:BA.1、BQ.1.1 和 XBB.1.5)的中和能力。我们观察到 HCWs 中存在广泛的中和活性,但未检测到针对 MERS-CoV 的中和活性。我们还观察到 SARS-CoV-2 和 SARS-CoV-1 的中和抗体滴度之间存在很强的相关性,但其他冠状病毒之间没有相关性。与 BA.1 和 BA.2 亚变种相比,针对较新的奥密克戎亚变种 BQ.1.1 和 XBB.1.5 的交叉中和滴度显著降低。另一方面,暴露后接种疫苗的 HCWs 对两种新的奥密克戎亚变种和 SARS-CoV-1 的中位交叉中和滴度相对较高,但未达到统计学意义。总之,我们的研究结果表明,坦桑尼亚 HCWs 对冠状病毒具有广泛的中和效力,并且由于 SARS-CoV-2 的暴露而检测到针对 SARS-CoV-1 的中和免疫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/10917759/a097b523233f/41598_2024_55989_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/10917759/c90fd86f5639/41598_2024_55989_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/10917759/a097b523233f/41598_2024_55989_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/10917759/c90fd86f5639/41598_2024_55989_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/10917759/a097b523233f/41598_2024_55989_Fig2_HTML.jpg

相似文献

1
Neutralizing immunity against coronaviruses in Tanzanian health care workers.坦桑尼亚医护人员对冠状病毒的中和免疫。
Sci Rep. 2024 Mar 6;14(1):5508. doi: 10.1038/s41598-024-55989-4.
2
Evaluation of cross-neutralizing immunity following COVID-19 primary series vaccination during the Omicron surge in Tanzania.奥密克戎变异株在坦桑尼亚流行期间评估 COVID-19 基础免疫系列接种后的交叉中和免疫反应。
J Med Virol. 2024 Aug;96(8):e29822. doi: 10.1002/jmv.29822.
3
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses.严重急性呼吸综合征冠状病毒 2 疫苗接种增强了对季节性人类冠状病毒的中和活性。
Clin Infect Dis. 2022 Aug 24;75(1):e653-e661. doi: 10.1093/cid/ciac057.
4
Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay.基于新型化学发光、病毒介导细胞病变法评估 BA.5 突破感染和三剂疫苗接种对奥密克戎亚变体的中和活性。
Microbiol Spectr. 2023 Aug 17;11(4):e0066023. doi: 10.1128/spectrum.00660-23. Epub 2023 Jun 13.
5
A cross-sectional study of SARS-CoV-2 antibodies among healthcare workers in a tertiary care hospital in Taiwan: implications for protection against the Omicron variants.台湾一家三级保健医院医护人员中 SARS-CoV-2 抗体的横断面研究:对奥密克戎变异体保护作用的启示。
BMC Infect Dis. 2024 May 27;24(1):529. doi: 10.1186/s12879-024-09411-z.
6
Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.儿童感染 SARS-CoV-2 或接种疫苗后对奥密克戎 BQ.1、BQ.1.1 和 XBB.1 变异株的中和作用。
Nat Commun. 2023 Dec 1;14(1):7952. doi: 10.1038/s41467-023-43152-y.
7
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.康复者接种 SARS-CoV-2 疫苗可增强对奥密克戎亚变体 BA.1、BA.2 和 BA.5 的中和能力,且可通过血清学检测中的抗-S 抗体浓度进行预测。
Front Immunol. 2023 Apr 25;14:1170759. doi: 10.3389/fimmu.2023.1170759. eCollection 2023.
8
Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.奥密克戎亚变体的中和敏感性、融合性和感染性。
Genome Med. 2022 Dec 29;14(1):146. doi: 10.1186/s13073-022-01151-6.
9
Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination.尽管基于原型的疫苗接种反复进行,但在 BA.5/ BF.7 突破性感染后,针对奥密克戎亚变种的中和作用随着病毒进化和老化而减弱。
Emerg Microbes Infect. 2023 Dec;12(2):2249121. doi: 10.1080/22221751.2023.2249121. Epub 2023 Sep 5.
10
Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.在接受 Evusheld 治疗的个体中,对 SARS-CoV-2 奥密克戎 BA.2、BA.2.75、BA.2.76、BA.5、BF.7、BQ.1.1 和 XBB.1.5 的血清中和作用。
J Med Virol. 2023 Jul;95(7):e28932. doi: 10.1002/jmv.28932.

引用本文的文献

1
Cross-neutralization ability of anti-MERS-CoV monoclonal antibodies against a variety of merbecoviruses.抗中东呼吸综合征冠状病毒单克隆抗体对多种默贝病毒的交叉中和能力。
Front Microbiol. 2025 Jul 16;16:1593095. doi: 10.3389/fmicb.2025.1593095. eCollection 2025.

本文引用的文献

1
Relative resistance of patient-derived envelope sequences to SERINC5-mediated restriction of HIV-1 infectivity.患者源性包膜序列对 SERINC5 介导的 HIV-1 感染性限制的相对抗性。
J Virol. 2023 Oct 31;97(10):e0082323. doi: 10.1128/jvi.00823-23. Epub 2023 Sep 28.
2
Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay.基于新型化学发光、病毒介导细胞病变法评估 BA.5 突破感染和三剂疫苗接种对奥密克戎亚变体的中和活性。
Microbiol Spectr. 2023 Aug 17;11(4):e0066023. doi: 10.1128/spectrum.00660-23. Epub 2023 Jun 13.
3
Pre-existing immunity to SARS-CoV-2 before the COVID-19 pandemic era in Cameroon: A comparative analysis according to HIV-status.
喀麦隆 COVID-19 大流行前针对 SARS-CoV-2 的预先存在免疫:根据 HIV 状况的比较分析。
Front Immunol. 2023 Mar 8;14:1155855. doi: 10.3389/fimmu.2023.1155855. eCollection 2023.
4
Impact of MERS-CoV and SARS-CoV-2 Viral Infection on Immunoglobulin-IgG Cross-Reactivity.中东呼吸综合征冠状病毒(MERS-CoV)和严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒感染对免疫球蛋白-IgG交叉反应性的影响。
Vaccines (Basel). 2023 Feb 26;11(3):552. doi: 10.3390/vaccines11030552.
5
Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines.对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的既有免疫力与灭活新冠疫苗诱导的强烈T细胞反应相关。
J Med Virol. 2023 Mar;95(3):e28642. doi: 10.1002/jmv.28642.
6
Treatment with integrase inhibitors alters SARS-CoV-2 neutralization levels measured with HIV-based pseudotypes in people living with HIV.使用整合酶抑制剂进行治疗会改变在感染HIV的人群中用基于HIV的假型所测得的SARS-CoV-2中和水平。
J Med Virol. 2023 Feb;95(2):e28543. doi: 10.1002/jmv.28543.
7
Clinical Validation of Standard Q COVID-19 Antigen and IgM/IgG Combo Kit Assay at a Tertiary Care Center in Northern India.印度北部一家三级护理中心对标准Q COVID-19抗原及IgM/IgG联合检测试剂盒的临床验证
J Lab Physicians. 2022 Apr 19;14(4):398-402. doi: 10.1055/s-0042-1744241. eCollection 2022 Dec.
8
Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB.奥密克戎亚变体BQ.1.1和XBB的体液免疫逃逸
Lancet Infect Dis. 2023 Jan;23(1):30-32. doi: 10.1016/S1473-3099(22)00816-7. Epub 2022 Dec 7.
9
Dissecting Naturally Arising Amino Acid Substitutions at Position L452 of SARS-CoV-2 Spike.解析 SARS-CoV-2 刺突蛋白位置 L452 处自然出现的氨基酸取代。
J Virol. 2022 Oct 26;96(20):e0116222. doi: 10.1128/jvi.01162-22. Epub 2022 Oct 10.
10
The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance.非洲不断演变的 SARS-CoV-2 疫情:来自快速扩展的基因组监测的洞察。
Science. 2022 Oct 7;378(6615):eabq5358. doi: 10.1126/science.abq5358.